CABOZANTINIB

Brand name:

• Cabometyx®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Ipsen Pty Ltd

Condition/indication:
(therapeutic use)

• Advanced clear cell variant renal cell carcinoma in combination with nivolumab

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to existing listing (Category 2)

Comment:

--

Other PBAC consideration:

--

Submission received for:

March 2024 PBAC meeting

Opportunity for consumer comment:

Open 22/11/2023 and close 31/01/2024 (see PBS Website)

PBAC meeting:

Held on 13/03/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

08/07/2026

5Lodgement of required documentation:

16/07/2026

Acceptance of complete documentation:

Under consideration

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred